Literature DB >> 16973340

Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors.

U Simmen1, O Kelber, S N Okpanyi, R Jaeggi, B Bueter, D Weiser.   

Abstract

Clinical studies with the fixed herbal combination product STW 5 (Iberogast) have indicated an efficacy comparable to metoclopramide (5-HT(3) antagonist) and cisapride (5-HT(4) agonist) in functional gastro-intestinal diseases like functional dyspepsia (FD) and irritable bowel syndrome (IBS). Since serotonin (5-HT(3) and 5-HT(4)) and muscarinic M(3) receptors are known to play a central role in the etiology of FD and IBS, the extracts contained in STW 5 and several of their phytochemical components were studied in vitro for binding affinities to these receptors of the intestine. STW 5 inhibited the binding of (3)H-GR113808 and (3)H-4-DAMP to 5-HT(4) and M(3) receptors, respectively, about 10 times more potently than the binding of (3)H-GR65630 to 5-HT(3) receptors. IC(50) values for STW 5 did correspond to extract dilutions of 1:1000 (M(3) binding) and 1:2000 (5-HT(4) binding). In addition, STW 5 also potently inhibited the binding to opioid receptors with an IC(50) value of 1:2000. Of the nine herbal extracts contained in STW 5, the fresh plant extract of bitter candy tuft (Iberis amara) selectively inhibited binding to M(3) receptors, while ethanolic extracts of celandine herb and chamomile flower were selective to 5-HT(4), and liquorice root to 5-HT(3) receptors. Binding affinities to human recombinant 5-HT(3), 5-HT(4) and M(3) receptors were qualitatively similar to those of the corresponding intestinal receptors. The benzylisoquinoline alkaloid berberine had significant inhibitory action on 5-HT(4) and M(3) binding, showing IC(50) values of 40 ng/ml (100 nM) and 200 ng/ml (500 nM), respectively, but is present in the extract of celandine herb only in traces, so that also for the celandine extract a cooperative effect of several phytochemical constituents can be assumed. These in vitro data indicate that 5-HT(4) (to a lesser degree 5-HT(3)), muscarinic M(3), and opioid receptors represent target sites for the treatment of FD and IBS with STW 5 (Iberogast).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973340     DOI: 10.1016/j.phymed.2006.03.012

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  12 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 2.  Herbal medicines for the management of irritable bowel syndrome: a comprehensive review.

Authors:  Roja Rahimi; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

Review 3.  The use of non-narcotic pain medication in pediatric gastroenterology.

Authors:  Adrian Miranda; Miguel Saps
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

Review 4.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

Review 5.  Management Options for Irritable Bowel Syndrome.

Authors:  Michael Camilleri
Journal:  Mayo Clin Proc       Date:  2018-12       Impact factor: 7.616

Review 6.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

Review 7.  Complementary and alternative medicines in irritable bowel syndrome: an integrative view.

Authors:  Oliver Grundmann; Saunjoo L Yoon
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

Review 8.  [STW 5/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome].

Authors:  Hans-Dieter Allescher; Hildebert Wagner
Journal:  Wien Med Wochenschr       Date:  2007

9.  STW 5 is effective in dextran sulfate sodium-induced colitis in rats.

Authors:  Walaa Wadie; Heba Abdel-Aziz; Hala F Zaki; Olaf Kelber; Dieter Weiser; Mohamed T Khayyal
Journal:  Int J Colorectal Dis       Date:  2012-05-06       Impact factor: 2.571

Review 10.  Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast.

Authors:  Heba Abdel-Aziz; Olaf Kelber; Gerhard Lorkowski; Martin Storr
Journal:  Planta Med       Date:  2017-08-31       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.